EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis

Nicholas A Tritos iD, Martin O Carlsson, Greisa Vila, Camilo Jimenez, Daria La Torre, Michael P Wajnrajch, Beverly Mk Biller, Lissette Cespedes, Karen K Miller

Endocrine Connections · 01.09.2025 · 14 (9)

DOI: 10.1530/ec-25-0247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Connections, online erschienen am 09.09.2025. Verfasst von Nicholas A Tritos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graphical Abstract Abstract Objective Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels.

Design

Retrospective cohort analysis of ACROSTUDY, a global surveillance study of patients with acromegaly receiving pegvisomant.

Methods

Cumulative incidence function was used to estimate disease-specific mortality, and regression analyses to characterized risk factors. Disease-specific standardized mortality ratios (SMR) were calculated; Poisson regression models characterized the association between disease-specific SMR, IGF-I, and other risk factors.

Results

2077 patients were followed (median: 4.1 years). Mortality (HR, 95% CI) secondary to cardiovascular/cerebrovascular causes increased with higher on-treatment IGF-I (1.97 (1.45–2.67), P < 0.0001) and older age at enrollment (1.10 (1.07–1.13), P < 0.0001). Mortality secondary to malignant (1.57 (1.17–2.09), P = 0.0024) or respiratory (1.64 (1.23–2.19), P = 0.0008) causes increased with higher on-treatment IGF-I. Younger attained age (0.93 (0.91–0.96), P < 0.0001), younger age (<35 vs > 50 years) at diagnosis (3.64 (1.33–9.93), P = 0.0117), higher on-treatment IGF-I (1.69 (1.12–2.55), P = 0.0127), and pituitary radiotherapy (2.25 (1.09–4.63), P = 0.0280) were associated with higher SMR (95% CI) for cardiovascular/cerebrovascular causes. Younger attained age (0.93 (0.89–0.96), P < 0.0001), higher IGF-I at enrollment (>2 × vs <1 × upper limit of normal: 4.89 (1.09–21.8), P = 0.0378), and malignancy at enrollment (7.05 (2.36–21.03), P = 0.0005) were associated with higher SMR (95% CI) for malignant causes. Younger age (35–50 vs >50 years) at diagnosis (4.50 (1.08–18.83), P = 0.0394) and sleep apnea (4.98 (1.34–18.53), P = 0.0168) were associated with higher SMR ratios for respiratory causes.

Conclusions

Younger age, higher on-therapy IGF-I, and radiotherapy were associated with higher SMR for cardiovascular/cerebrovascular causes, highlighting the importance of achieving IGF-I normalization.

Schlagwörter

Stichwörter der Autor:innen

acromegalymortalitypegvisomantradiotherapy

Autor:innen und Institutionen

  • Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Pfizer Endocrine Care, Inc, New York, NY, USA.
  • Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pfizer srl, Rome, Italy.
  • Department of Pediatrics, New York University Grossman School of Medicine, New York, NY, USA.

ORCID-Profile: Nicholas A Tritos

Zitieren

APA

Tritos, N. A., Carlsson, M. O., Vila, G., Jimenez, C., La Torre, D., Wajnrajch, M. P., Biller, B. M., Cespedes, L., & Miller, K. K. (2025). Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Endocrine Connections, 14(9). https://doi.org/10.1530/ec-25-0247

Vancouver

Tritos NA, Carlsson MO, Vila G, Jimenez C, La Torre D, Wajnrajch MP, et al. Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Endocrine Connections. 2025;14(9). doi:10.1530/ec-25-0247

BibTeX
@article{Tritos2025,
  author = {Tritos, Nicholas A and Carlsson, Martin O and Vila, Greisa and Jimenez, Camilo and La Torre, Daria and Wajnrajch, Michael P and Biller, Beverly Mk and Cespedes, Lissette and Miller, Karen K},
  title = {Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis},
  journal = {Endocrine Connections},
  year = {2025},
  volume = {14},
  number = {9},
  doi = {10.1530/ec-25-0247}
}
Kostenlos starten →